Market access roundup: The US fights back against price hikesDon’t expect the US government’s war on drug pricing to go away any time soon – for once Share XMarket access roundup: The US fights back against price hikeshttps://pharmaphorum.com/views-analysis-market-access/market-access-roundup-the-us-fights-back-against-price-hikes/
Mandatory or voluntary? A sticking point for European HTAThe long road to unified European Health Technology Assessment (HTA) is continuing. It has become clear that the Share XMandatory or voluntary? A sticking point for European HTAhttps://pharmaphorum.com/views-analysis-market-access/mandatory-or-voluntary-a-sticking-point-for-european-hta/
2018 in review: Governments start taking access seriouslyMarket access has become a key focus for governments across the globe in 2018 – though as ever Share X2018 in review: Governments start taking access seriouslyhttps://pharmaphorum.com/views-analysis-market-access/2018-in-review-governments-start-taking-access-seriously/
Pharma hopes for best, fears the worst, as Brexit vote nearsThe deadline for Brexit is edging closer, and politicians in the UK are struggling to come to terms Share XPharma hopes for best, fears the worst, as Brexit vote nearshttps://pharmaphorum.com/views-analysis-market-access/pharma-hopes-best-fears-worst-brexit-vote-nears/
Late to the party but we brought friends: BeneLuxA’s horizon scanning initiativeIt can feel good to know what is coming your way; that’s no different for new medicines and Share XLate to the party but we brought friends: BeneLuxA’s horizon scanning initiativehttps://pharmaphorum.com/views-analysis-market-access/joint-horizon-scanning/
How the NHS got ahead of the curve with CAR-TThe UK’s pharma industry has welcomed the NHS’ fast adoption of the latest CAR-T cancer therapies. Richard Staines Share XHow the NHS got ahead of the curve with CAR-Thttps://pharmaphorum.com/views-analysis-oncology/nhs-got-ahead-curve-car-t/
Ensuring access to medicines is good for everyone – pharma includedBecause its publicity that money just can’t buy, because it will attract a new breed of investors – Share XEnsuring access to medicines is good for everyone – pharma includedhttps://pharmaphorum.com/views-analysis-market-access/ensuring-access-medicines/
Can managed access agreements help unlock access through the NICE Highly Specialised Technology Appraisal Process?The National Institute for Health and Care Excellence (NICE) process for single technology appraisals (STA) has been established Share XCan managed access agreements help unlock access through the NICE Highly Specialised Technology Appraisal Process?https://pharmaphorum.com/market-access-2/can-managed-access-agreements-help-unlock-access-through-the-nice-highly-specialised-technology-appraisal-process/
Balancing expectations: An unmet need in the orphan disease arenaThere are between 6000 and 8000 rare diseases in the world, and one in ten people in Europe Share XBalancing expectations: An unmet need in the orphan disease arenahttps://pharmaphorum.com/views-analysis-market-access/balancing-expectations-rare-disease-arena/
